Listed by the USPTO as NICKOL, GARY B
Tech Center 1600 • Art Units: 1641 1642 1643 1645 1646
This examiner grants 47% of resolved cases
NICKOL, GARY B is assigned to tech center 1600 and art unit 1641. The record covers 73 resolved cases, with an allowance rate of 46.6%. The median time to allowance is 1381 days, while interview lift is 33.3%. The positive interview measure suggests that interviews may be a significant part of an effective prosecution approach in this record.
The leading applicants are The Regents of the University of California, Hoffmann-La Roche Inc., and Novartis AG. The listed firms are STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., GOODWIN PROCTER LLP, and McBee Moore & Vanik, IP, LLC. Because the resolved-case record is limited to 73 cases, practitioners should treat these measures as a focused reference for this examiner rather than a broad prediction for every application.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18533714 | BISPECIFIC ANTI-CCL2 ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18280970 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF MYASTHENIA GRAVIS | Final Rejection | Hoffmann-La Roche Inc. |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Final Rejection | NOVARTIS AG |
| 18275616 | ANTI-IL1RAP ANTIBODIES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18288696 | SELF-ACTIVATING FÖRSTER RESONANCE ENERGY TRANSFER (saFRET) BIOSENSORS AND METHODS FOR MAKING AND USING THEM | Non-Final OA | The Regents of the University of California |
| 18552141 | SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION | Final Rejection | The Regents of the University of California |
| 17251287 | SINGLE-CHAIN BISPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | Final Rejection | The Regents of the University of California |
| 18531168 | TARGETING ANTI-HUMAN PD 1H/VISTA TO TREAT HEMATOLOGIC DISORDERS | Final Rejection | VANDERBILT UNIVERSITY |
| 18273796 | BLUE-GREEN ALGAE-CONTAINING TABLET | Non-Final OA | DIC Corporation |
| 18553703 | METHODS FOR DETERMINING TUMOR IMMUNE STATUS | Non-Final OA | Duke University |
| 18701356 | ACTIVATABLE ANTI-CD3, ANTI-EGFR, HETEROMULTIMERIC BISPECIFIC POLYPEPTIDE COMPLEX | Non-Final OA | CytomX Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.6% of resolved applications examined by Gary B Nickol were allowed (73 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +33.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Gary B Nickol took 1,381 days on average from filing to allowance.
Gary B Nickol examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
